New Shire CEO Has Big Ophthalmology Plans; SARcode Sets The Stage
This article was originally published in The Pink Sheet Daily
Executive Summary
With its third acquisition this year, Shire gains Phase III Lifitegrast in development for dry eye disease. It expects to launch the product in the U.S. in 2016.
You may also be interested in...
Quick Resubmission Has Shire Seeking Third Quarter Lifitegrast OK
Having produced positive top-line data from a third Phase III trial within two weeks of FDA's complete response letter, Shire made quick work of its reply to the agency on the dry eye disease candidate.
Shire Uses Foresight To Expand In Ophthalmology
Shire acquired Foresight Biotherapeutics for $300 million, gaining a late-stage drug for pink eye that will be a commercial complement to lifitegrast.
Shire Eyes Lifitegrast For Growth But Still Gets Dry Reception
The specialty pharma expressed confidence about the late-stage dry-eye drug lifitegrast at a Dec. 10 R&D day, but analysts remain wary about whether Shire can hit sales goals based on its current pipeline.